These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 370527)

  • 1. A double-blind trial of bromocriptine in Parkinson's disease.
    Mackenzie RA; Lance JW
    Med J Aust; 1978 Nov; 2(3 Suppl):27-8. PubMed ID: 370527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of bromocriptine in the treatment of Parkinson's disease.
    Mackenzie RA; Lance JW
    Clin Exp Neurol; 1978; 15():228-36. PubMed ID: 386307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
    Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
    Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 7. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromocryptine in levodopa response-losing parkinsonism. A double blind study.
    Jansen EN
    Eur Neurol; 1978; 17(2):92-9. PubMed ID: 344042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
    Jellinger K
    J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine and the clinical spectrum of Parkinson's disease.
    Riopelle RJ
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):455-9. PubMed ID: 3676920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study.
    Toyokura Y; Mizuno Y; Kase M; Sobue I; Kuroiwa Y; Narabayashi H; Uono M; Nakanishi T; Kameyama M; Ito H
    Acta Neurol Scand; 1985 Aug; 72(2):157-70. PubMed ID: 3901650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.
    Godwin-Austen RB; Smith NJ
    J Neurol Neurosurg Psychiatry; 1977 May; 40(5):479-82. PubMed ID: 330825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of the on-off syndrome in Parkinsonism with low dose bromocriptine in combination with levodopa.
    Bateman DN; Coxon A; Legg NJ; Reid JL
    J Neurol Neurosurg Psychiatry; 1978 Dec; 41(12):1109-13. PubMed ID: 366085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromocriptine in the management of end of dose deterioration in Parkinson's disease.
    Grimes JD; King DB; Kofman OS; Molina-Negro P; Wilson AF; Bouchard S
    Can J Neurol Sci; 1984 Nov; 11(4):452-6. PubMed ID: 6518428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease.
    Laihinen A; Rinne UK; Suchy I
    Acta Neurol Scand; 1992 Dec; 86(6):593-5. PubMed ID: 1481646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.
    Bouchard S
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):460-5. PubMed ID: 3676921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.